Advertisement
Review article|Articles in Press

Obesity, metabolic and bariatric surgery, and cancer prevention: what do we need to learn and how do we get there?

Published:February 06, 2023DOI:https://doi.org/10.1016/j.soard.2023.01.029

      Abstract

      Obesity and associated metabolic dysfunction are on the rise in the United States and around the world. Metabolic dysfunction often leads to chronic disease, including cancer. Recent evidence suggests that weight loss among individuals with obesity may decrease cancer risk. Metabolic and bariatric surgery (MBS) leads to greater maximum and sustained weight loss than nonsurgical dietary strategies and demonstrates the most convincing evidence that weight loss lowers cancer risk. Caloric restriction diets combined with GLP-1 receptor agonists demonstrate weight loss intermediate between MBS and other nonsurgical diet strategies so long as individuals consistently take the medication. Weight regain after initial loss is a major problem with all weight loss strategies. To better prevent cancer in individuals with obesity, we need to individualize weight loss strategies, determining what strategy works for a given individual and how to implement it. We need to learn (1) what an individual’s impediments to initial and sustained weight loss are; (2) what the optimal weight loss strategy, be it diet modification, diet modification + medication, or MBS followed by diet modification, is; (3) how exercise(s) should be incorporated into weight loss strategies; (4) where medications fit into the treatment strategy of individuals with obesity; and (5) what the mechanisms driving the influence of MBS on cancer risk are. We also need to (6) explore expanding the eligibility of MBS to individuals with a body mass index <35 kg/m2. Answers to these questions require a better understanding of how MBS impacts cancer risk, including in which groups (women versus men, which racial and ethnic groups, which cancers, which MBS procedure) MBS works best to reduce risk. The National Cancer Institute, through new funding opportunities, hopes to advance our understanding of how obesity drives cancer risk and how individuals with obesity can prevent cancer development and, among those with cancer, prevent disease recurrence.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ward Z.J.
        • Bleich S.N.
        • Cradock A.L.
        • et al.
        Projected U.S. state-level prevalence of adult obesity and severe obesity.
        N Engl J Med. 2019; 38 (1): 2440-2450
        • National Cancer Institute
        Annual plan & budget proposal for fiscal year 2022.
        National Institutes of Health, Bethesda (MD)2022
        • Calle E.E.
        • Rodriguez C.
        • Walker-Thurmond K.
        • Thun M.J.
        Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.
        N Engl J Med. 2003; 348: 1625-1638
        • National Cancer Institute
        Cancer trends progress report: cancer survivors.
        National Institutes of Health, Bethesda (MD)2022
        • Lauby-Secretan B.
        • Scoccianti C.
        • Loomis D.
        • et al.
        Body fatness and cancer--viewpoint of the IARC Working Group.
        N Engl J Med. 2016; 375: 794-798
        • Wright M.E.
        • Chang S.C.
        • Schatzkin A.
        • et al.
        Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality.
        Cancer. 2007; 109: 675-684
        • Cohen S.S.
        • Palmieri R.T.
        • Nyante S.J.
        • et al.
        Obesity and screening for breast, cervical, and colorectal cancer in women: a review.
        Cancer. 2008; 112: 1892-1904
        • Maruthur N.M.
        • Bolen S.
        • Brancati F.L.
        • Clark J.M.
        Obesity and mammography: a systematic review and meta-analysis.
        J Gen Intern Med. 2009; 24: 665-677
        • Lee K.
        • Kruper L.
        • Dieli-Conwright C.M.
        • Mortimer J.E.
        The impact of obesity on breast cancer diagnosis and treatment.
        Curr Oncol Rep. 2019; 21: 41
        • Renehan A.G.
        • Tyson M.
        • Egger M.
        • Heller R.F.
        • Zwahlen M.
        Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.
        Lancet. 2008; 371: 569-578
        • Uppot R.N.
        Technical challenges of imaging & image-guided interventions in patients with obesity.
        Br J Radiol. 2018; 9120170931
        • Carlsson L.M.S.
        • Sjoholm K.
        • Jacobson P.
        • et al.
        Life expectancy after bariatric surgery in the Swedish Obese Subjects study.
        N Engl J Med. 2020; 383: 1535-1543
        • Srivastava G.
        • Buffington C.
        Early weight loss outcomes from a newly established hospital-affiliated specialized obesity care delivery model in Central Florida.
        Int J Obes (Lond). 2019; 43: 132-138
        • Moss S.A.
        • Serbetci D.
        • O'Brien K.
        • Alexi N.
        The validated features of psychological interventions for weight loss: an integration.
        Behav Med. 2022; 48: 147-161
        • Williamson D.A.
        • Bray G.A.
        • Ryan D.H.
        Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?.
        Obesity (Silver Spring). 2015; 23: 2319-2320
        • Ryan D.H.
        • Yockey S.R.
        Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over.
        Curr Obes Rep. 2017; 6: 187-194
        • Look A.R.G.
        • Yeh H.C.
        • Bantle J.P.
        • et al.
        Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the look AHEAD randomized clinical trial.
        Obesity (Silver Spring). 2020; 28: 1678-1686
        • Chlebowski R.T.
        • Luo J.
        • Anderson G.L.
        • et al.
        Weight loss and breast cancer incidence in postmenopausal women.
        Cancer. 2019; 125: 205-212
        • Youssef M.R.
        • Reisner A.S.C.
        • Attia A.S.
        • et al.
        Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer - pooled results of 24 million cohorts.
        Oral Oncol. 2021; 112105085
        • Shuval K.
        • Hebert E.T.
        • Siddiqi Z.
        • et al.
        Impediments and facilitators to physical activity and perceptions of sedentary behavior among urban community residents: the Fair Park Study.
        Prev Chronic Dis. 2013; 10: E177
        • Cao C.
        • Yang S.
        • Zhou Z.
        GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.
        Endocrine. 2019; 66: 157-165
        • Arvanitakis K.
        • Koufakis T.
        • Kotsa K.
        • Germanidis G.
        How far beyond diabetes can the benefits of glucagon-like peptide-1 agonists go? A review of the evidence on their effects on hepatocellular carcinoma.
        Cancers. 2022; 14: 4651
        • Sjostrom L.
        Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery.
        J Intern Med. 2013; 273: 219-234
        • Arterburn D.
        • Wellman R.
        • Emiliano A.
        • et al.
        Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study.
        Ann Intern Med. 2018; 169: 741-750
        • Jastreboff A.M.
        • Aronne L.J.
        • Ahmad N.N.
        • et al.
        Tirzepatide once weekly for the treatment of obesity.
        N Engl J Med. 2022; 387: 205-216
        • Hall K.D.
        • Kahan S.
        Maintenance of lost weight and long-term management of obesity.
        Med Clin North Am. 2018; 102: 183-197
        • Sauter E.R.
        • Heckman-Stoddard B.
        Metabolic surgery and cancer risk: an opportunity for mechanistic research.
        Cancers (Basel). 2021; 13: 3183
        • Eisenberg D.
        • Shikora S.A.
        • Aarts E.
        • et al.
        2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery.
        Surg Obes Relat Dis. 2022; 18: 1345-1356
        • Frikke-Schmidt H.
        • O’Rourke R.W.
        • Lumeng C.N.
        • Sandoval D.A.
        • Seeley R.J.
        Does bariatric surgery improve adipose tissue function?.
        Obesity Rev. 2016; 17: 795-809